Cardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus
Key Points:
- Compares the cardiovascular benefits and risks of dapagliflozin and empagliflozin.
- Assesses heart failure, atherosclerotic events, and overall mortality in diabetic patients.
- Aims to guide optimal SGLT2 inhibitor selection for cardiovascular protection.
Description
This study compares cardiovascular outcomes in patients with diabetes mellitus treated with dapagliflozin versus empagliflozin. By evaluating efficacy and safety, the research aims to determine the superior SGLT2 inhibitor for reducing cardiovascular risks and improving patient health.
Be the first to review “Cardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus”
Reviews
There are no reviews yet.